EPH48 evolution of polypharmacy and prescribed drug expenditure: the case of an insured poor population in the colombian caribbean during 2018-2021

EVOLUTION OF POLYPHARMACY AND PRESCRIBED DRUG EXPENDITURE: THE CASE OF AN INSURED POOR POPULATION IN THE COLOMBIAN CARIBBEAN DURING 2018-2021 Gamero K,1 Alvis J,2 Mercado Fernandez JC,3 Paz Wilches J,4 Alvis Guzman N5 1 Distribuciones Pharmaser, Cali, VAC, Colombia, 2 Distribuciones Pharmaser, Cartagena, BOL, Colombia, 3 MUTUALSER EPS - University of Cartagena - Clínica Crecer, Cali, VAC, Colombia, 4 Mutual SER EPS, Cartagena, Colombia, 5 ALZAK Foundation- Universidad De La Costa, Barranquilla, Colombia Objectives: The aim of this study is to estimate the impact of the variation in the prevalence of polypharmacy rate in the prescribed drug expenditure (PDE). during 2018-2021. Methods: Cross sectional descriptive study of polymedicated patients (PP) during 2018-2021 was developed. Data was extracted from the individual outpatient dispense records from a health insurance company in Colombia. Polypharmacy and hypermedication were defined when patients consumed $5 and $10 medications in at least a continuous period. The number of patients attended, the number of medications per patient, defined daily doses (DDD) per patient (TI) and cost per DDD are calculated. Finally, a simulation of PDE of 2021 is developed in which the prevalence of polypharmacy is neutralized between 2018 and 2021 and keep the other variables constant. Results: Polypharmacy rate was 26,82% in 2018 and 31,17% in 2021. The PDE in 2015 constant US$ dollars for PP increased from $653,240 to $1,605,527. Neutralizing the prevalence of polypharmacy, the PDE of 2021 was $1,372,664, 110% higher than the PDE of 2018 due to the cost per DDD increased from $0.028 to $0.048, despite TI decreased from 333 to 286 but, lower than 2021 PDE because 2018 polypharmacy is lower. Conclusions: Polypharmacy has had a significant impact on the increase in PDE of the insurance company because in 2021 the cost per DDD increased as a consequence of the prescription of more expensive health technologies. The design of interventions and strict protocols need to be developed to mitigate the risk of non rational prescriptions in polymedicated patients and controlling the evolution of PDE.

• Autores: Gamero, K.; Alvis, J.; JC Mercado, Fernandez; Paz Wilches, J.; Alvis Guzman, N .
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2023
• Institución: Corporación Universidad de la Costa
• Repositorio: REDICUC - Repositorio CUC
• Idioma: eng
• OAI Identifier: oai:repositorio.cuc.edu.co:11323/13599
• Acceso en línea: https://hdl.handle.net/11323/13599; https://repositorio.cuc.edu.co/
• Palabra clave: Patients; Medications; Polypharmacy
• Rights: openAccess
• License: Atribución 4.0 Internacional (CC BY 4.0)